MtoZ Biolabs launches PhIP-Seq platform for antibody screening

MtoZ Biolabs said it has launched a PhIP-Seq platform in Boston to support high-throughput antigen epitope screening, autoantibody discovery and biomarker research. The service is aimed at researchers comparing antibody responses across diseases, treatments and immune exposures.

Why it matters: - PhIP-Seq expands antibody research beyond single-target tests by letting researchers screen broad antigen spaces in one experiment. - The platform is designed to help identify candidate antigens, linear epitopes and disease-associated immune signals in complex samples. - The service targets universities, research institutes and biopharmaceutical companies working on autoimmunity, infection, vaccines and biomarker discovery.

What happened: - MtoZ Biolabs launched a PhIP-Seq platform in Boston on June 21, 2026. - The platform provides analysis support for antigen epitope screening, antibody repertoire profiling, autoantibody discovery and biomarker research. - The company framed the service as a way to support researchers when ELISA, western blotting, immunofluorescence and protein microarrays are too limited for broad screening.

The details: - PhIP-Seq combines phage-displayed peptide libraries, antibody immunoprecipitation and high-throughput sequencing to analyze antibody binding. - The workflow uses antibody-containing samples such as serum, plasma or cerebrospinal fluid. - Antibody-recognized phages are enriched, then their DNA sequences are sequenced to infer candidate antigens or linear epitopes. - The platform can use human proteome-related libraries, autoimmune-associated epitope libraries, viral libraries, bacterial libraries, fungal libraries, pathogen-specific libraries, vaccine-related libraries and customized peptide libraries. - MtoZ Biolabs said the platform can support sample testing, phage display sequencing assays, data processing, peptide enrichment analysis, candidate antigen screening, result visualization and customized bioinformatics analysis. - The platform can also help with study design choices, including sample type, grouping and antigen peptide library selection. - The company said the service can be used for high-throughput antigen epitope screening, antibody response repertoire analysis, autoantibody screening, pathogen antibody repertoire analysis, vaccine immune evaluation and disease-associated antigen discovery.

Between the lines: - The launch reflects growing demand for discovery tools that can evaluate many possible antibody targets before researchers narrow to a final validation set. - MtoZ Biolabs is positioning the platform as an early-stage research service, not a replacement for downstream confirmation methods. - The emphasis on library selection and study design suggests the usefulness of PhIP-Seq depends heavily on defining the biological question before sequencing begins. - The company also stressed that candidate findings should be validated with independent experimental methods before they are treated as final conclusions.

What's next: - Researchers interested in the platform are being invited to discuss sample type, study grouping, sample size and research goals with MtoZ Biolabs. - The company said those inputs will help determine an appropriate PhIP-Seq analysis plan. - More information is available on the company’s website.

The bottom line: - MtoZ Biolabs is betting that demand for high-throughput immune profiling will keep rising as researchers look for faster ways to map antibody responses across disease, infection and vaccine studies.